The specific activity of lenalidomide in MDS with del(5q) is now explained by its capacity to target a further CDR encoded protein, casein kinase 1 alpha (CK1α), for proteasomal degradation [58]. Here, CSNK1A1 is linked to myelodysplastic syndrome.